Over the past year, and for the first time ever, the US Food and Drug Administration
approved 2 drugs specifically for the treatment of lupus nephritis (LN). As the lupus …

Background In adults with active lupus nephritis, the efficacy and safety of intravenous
belimumab as compared with placebo, when added to standard therapy (mycophenolate …

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …

Since its incorporation into clinical practice in the 1950s, the percutaneous kidney biopsy
has played an important role in advancing our understanding of lupus nephritis (LN). The …

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a
Controversies Conference on glomerular diseases in November 2017. The conference …

We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis
(BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial, in which 448 patients …

Background Treatment response in lupus nephritis (LN) is defined clinically, without
consideration of renal histology. Few studies have systematically examined histologic …

In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative
brought a diverse panel of experts in glomerular diseases together to discuss the 2012 …

The optimal duration of maintenance immunosuppressive therapy for patients with lupus
nephritis who have achieved clinical remission has not been established. Furthermore …

Results Across 16 focus groups, 134 participants (range, 19–85 years old; 51% women),
including 101 patients and 33 caregivers, identified 58 outcomes. The ten highest-ranked …